Igiv3i grifols 10% (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
63 | Idiopathic thrombocytopenic purpura | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00511147 (ClinicalTrials.gov) | May 2008 | 1/8/2007 | IGIV Study for Chronic ITP Patients Ages 3-70 | A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura | Idiopathic Thrombocytopenic Purpura | Biological: IGIV3I Grifols 10% | Grifols Biologicals Inc. | Instituto Grifols, S.A. | Completed | 3 Years | 70 Years | All | 64 | Phase 3 | United States;Canada;India;Puerto Rico |